Sibaji Biswas
-
Syngene International posts Rs 519 Cr PAT for the full year ending March 31, 2024
Fourth quarter revenue from operations declined 8 per cent year-on-year to Rs 917 cr, PAT increased 6 per cent to…
Read More » -
Syngene to acquire multi-modal facility from Stelis Biopharma
To add 20,000 litres of installed biologics drug substance manufacturing capacity Syngene announced the acquisition of Unit 3 biologics manufacturing…
Read More » -
Syngene posts Rs 803 Cr revenue, PAT up to Rs 110 Cr
In manufacturing, the highlight of the quarter was the successful inspection of biologics facilities by the US FDA, EMA and…
Read More »
